HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B (HCM:NASDAQ)
· seekingalpha.com
HUTCHMED inks exclusive GSK licensing deal for KRAS/EGFR cancer therapy HMPL-A830, worth up to $1.295B.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...